Response To the Letter to the Editor Entitled “First Report of Daratumumab Therapy in Refractory THSD7A-Positive Membranous Nephropathy”
Authors:
- Fatima AyubFAFatima Ayub
- John ArthurJAJohn Arthur
- Rajibul HasanRHRajibul Hasan
- Luis A. JuncosLJLuis A. Juncos
- Joseph Hunter HolthoffJHJoseph Hunter Holthoff
Open Access
- 18 October 2025
- journal article
- Published by Elsevier in Kidney International Reports
- Vol. 10 (12) , 4316-4317
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- First Report of Daratumumab Therapy in Refractory THSD7A-Positive Membranous NephropathyKidney International Reports, 2025
- Plasma Cell–Directed Rescue With Bortezomib in Refractory Antiphospholipase A2 Receptor–Positive Membranous NephropathyKidney International Reports, 2025
- Plasma cell–directed therapy for rituximab-refractory PLA2R+ membranous nephropathyNephrology Dialysis Transplantation, 2023
- Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathyKidney International, 2021
- Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathyJournal Of Nephrology, 2014